NCT04917224: LUNG STAAR

Study of LUNG Stereotactic Adaptive Ablative Radiotherapy

Withdrawn NA Last updated 26 September 2023

What this trial tests

NA trial testing Stereotactic Adaptive Ablative Radiotherapy at 50 Gy (Gray) in Lung Cancer. Withdrawn.

Timeline

2 May 2022

Primary endpoint
1 October 2031

1 October 2032

Quick facts

Lead sponsor	Baptist Health South Florida
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Start date	2 May 2022
Primary completion	1 October 2031
Estimated completion	1 October 2032

Drugs / interventions tested

• Stereotactic Adaptive Ablative Radiotherapy at 50 Gy (Gray)
• Stereotactic Adaptive Ablative Radiotherapy at 60 Gy (Gray)

Conditions studied

• Lung Cancer — all drugs for Lung Cancer →
• Lung Tumor — all drugs for Lung Tumor →

Sponsor

Baptist Health South Florida — full company profile →

Who can join

18 and older, any sex, with Lung Cancer or Lung Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The proposed study expands on the principles of SBRT (Stereotactic Body Radiation Therapy) and SABR (Stereotactic Ablative Radiotherapy) for centrally located NSCLC (Non-Small Cell Lung Cancer) to further optimize outcomes in this patient population with utilization of the adaptive workflow to maintain tumor control rates but decrease the incidence and grade of treatment-related toxicities.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

1. Stereotactic Magnetic Resonance-Guided Adaptive and Non-Adaptive Radiotherapy on Combination MR-Linear Accelerators: Current Practice and Future Directions.
   Bryant JM, Weygand J, Keit E, Cruz-Chamorro R, et al · · 2023 · cited 24× · PMID 37046741 · DOI 10.3390/cancers15072081
2. Magnetic Resonance-Guided Stereotactic Body Radiation Therapy/Hypofractionated Radiation therapy for Metastatic and Primary Central and Ultracentral Lung Lesions.
   Sandoval ML, Sim AJ, Bryant JM, Bhandari M, et al · · 2023 · cited 15× · PMID 37159821 · DOI 10.1016/j.jtocrr.2023.100488
3. Adaptive hypofractionted and stereotactic body radiotherapy for lung tumors with real-time MRI guidance.
   Bryant JM, Sim AJ, Feygelman V, Latifi K, et al · · 2023 · cited 9× · PMID 36776319 · DOI 10.3389/fonc.2023.1061854
4. Prospective In Silico Evaluation of Cone-Beam Computed Tomography-Guided StereoTactic Adaptive Radiation Therapy (CT-STAR) for the Ablative Treatment of Ultracentral Thoracic Disease.
   Schiff JP, Laugeman E, Stowe HB, Zhao X, et al · · 2023 · cited 5× · PMID 37206996 · DOI 10.1016/j.adro.2023.101226
5. Initial clinical experience building a dual CT- and MR-guided adaptive radiotherapy program.
   Price AT, Schiff JP, Laugeman E, Maraghechi B, et al · · 2023 · cited 4× · PMID 37529627 · DOI 10.1016/j.ctro.2023.100661
6. Outcome and safety of SBRT in centrally and ultra-centrally located lung tumours: A PRISMA-based systematic review and Meta-Analysis.
   Wiegreffe S, Adebahr S, Schimek-Jasch T, Layer JP, et al · · 2026 · PMID 41953588 · DOI 10.1016/j.ctro.2026.101151
7. Organs at risk proximity in central lung stereotactic ablative radiotherapy: A comparison of four-dimensional computed tomography and magnetic resonance-guided breath-hold delivery techniques.
   Giraud N, Tekatli H, Schneiders FL, van Sornsen de Koste JR, et al · · 2025 · PMID 40242808 · DOI 10.1016/j.phro.2025.100761